Cargando…

Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease

OBJECTIVE: To evaluate the efficacy and safety of finerenone and sodium-glucose cotransporter-2 inhibitors (SGLT2i) on reducing new-onset of atrial fibrillation (AF) in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). METHOD: We searched the PubMed, Cochrane Library, W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yaofu, Wang, Junheng, Jiang, Li, Wang, Tongxin, Li, Zhuang, Fu, Xiaozhe, Huang, Weijun, Xiao, Yonghua, Wang, Shidong, Zhao, Jinxi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609222/ https://www.ncbi.nlm.nih.gov/pubmed/36303247 http://dx.doi.org/10.1186/s13098-022-00929-3

Ejemplares similares

Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease
por: Zhang, Yaofu, et al.
Publicado: (2022)

Effect of RG (Coptis root and ginseng) formula in patients with type 2 diabetes mellitus: a study protocol for a randomized controlled and double-blinding trial
por: Jiang, Li, et al.
Publicado: (2022)

Qingre Yiqi Method along with Oral Hypoglycemic Drugs in Treating Adults with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Jiang, Li, et al.
Publicado: (2021)

Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis
por: Li, Xuefeng, et al.
Publicado: (2022)

Complementary actions of finerenone and SGLT2‐i on renal outcomes?: An urgent need for more information
por: Rebelos, Eleni, et al.
Publicado: (2022)

SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study
por: Li, Jiang, et al.
Publicado: (2023)

Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus
por: Lv, Ruolin, et al.
Publicado: (2023)

Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
por: Zhao, Li-Min, et al.
Publicado: (2022)

The effectiveness of SGLT2 inhibitor in the incidence of atrial fibrillation/atrial flutter in patients with type 2 diabetes mellitus/heart failure: a systematic review and meta-analysis
por: Wang, Miaomiao, et al.
Publicado: (2022)

Treatment options of traditional Chinese patent medicines for dyslipidemia in patients with prediabetes: A systematic review and network meta-analysis
por: Jiang, Li, et al.
Publicado: (2022)

Implications of SGLT Inhibition on Redox Signalling in Atrial Fibrillation
por: Bode, David, et al.
Publicado: (2021)

Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus
por: Jin, Tao, et al.
Publicado: (2023)

Comparison of New-Onset Diabetes Mellitus among Patients with Atrial Fibrillation or Atrial Flutter
por: Hu, Wei-Syun, et al.
Publicado: (2020)

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
por: Bonora, Benedetta Maria, et al.
Publicado: (2021)

The Role of Finerenone in the Management of Diabetic Nephropathy
por: Veneti, Stavroula, et al.
Publicado: (2021)

Potassium management with finerenone: Practical aspects
por: Wanner, Christoph, et al.
Publicado: (2022)

Protocol of BEYOND trial: Clinical BEnefit of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in rhYthm cONtrol of atrial fibrillation in patients with diabetes mellitus
por: Lee, Kyuhyun, et al.
Publicado: (2023)

SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials
por: Li, Wen-jie, et al.
Publicado: (2020)

Finerenone for chronic kidney disease associated with type 2 diabetes with albuminuria
Publicado: (2023)

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
por: Bode, David, et al.
Publicado: (2021)

Cardiorenal benefits of finerenone: protecting kidney and heart
por: González-Juanatey, José R., et al.
Publicado: (2023)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Use of SGLT2i and ARNi in patients with atrial fibrillation and heart failure in 2021–2022: an analysis of real-world data
por: Alonso, Alvaro, et al.
Publicado: (2023)

Cerebrovascular, Cognitive and Cardiac Benefits of SGLT2 Inhibitors Therapy in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus: Results from a Global Federated Health Network Analysis
por: Proietti, Riccardo, et al.
Publicado: (2023)

Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis
por: Zhou, Zien, et al.
Publicado: (2021)

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2020)

Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

New‐onset atrial fibrillation after atrial ischemia
por: Kondo, Yusuke, et al.
Publicado: (2019)

The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
por: Tilinca, Mariana Cornelia, et al.
Publicado: (2021)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

Risks of Pneumonia in COPD Patients with New-Onset Atrial Fibrillation
por: Wang, Ya-Hui, et al.
Publicado: (2018)

Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes
por: Ruilope, Luis M., et al.
Publicado: (2022)

Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes
por: Ashjian, Emily, et al.
Publicado: (2023)

Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands
por: Quist, Sara W., et al.
Publicado: (2023)

Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
por: Zheng, Ru-Jie, et al.
Publicado: (2022)

Incidence of atrial fibrillation in elderly patients with type 2 diabetes mellitus
por: Matsumoto, Chisa, et al.
Publicado: (2022)

Surgical ablation for atrial fibrillation: impact of Diabetes Mellitus type 2
por: Kogan, Alexander, et al.
Publicado: (2023)

A Systematic Review and Meta-Analysis on the Efficacy and Safety of Finerenone Therapy in Patients with Cardiovascular and Chronic Kidney Diseases in Type 2 Diabetes Mellitus
por: Jyotsna, FNU, et al.
Publicado: (2023)

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rng36mkuq48f6r9e0tkhu7or8r